Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.40 |
| ▸ | PPM1B | O75688 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 2/20 | 0.32 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844707 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL468523 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL468432 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL20679256 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15378131 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL468430 | 1.00 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL2116961 | 0.87 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15914393 | 0.87 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL458523 | 0.87 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15914391 | 0.87 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576531-A1 | ENANTIOMERICALLY PURE AMINES | Nabriva Therapeutics AG (AT) | 2013-04-10 | — | — | EP | claimed |
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2013-03-21 | — | — | US | claimed |
| WO-2011146953-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2011-12-01 | — | — | WO | claimed |
| US-8987498-B2 | Enantiomerically pure amines | NABRIVA THERAPEUTICS AG (AT) | 2015-03-24 | — | — | US | disclosed |
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | NABRIVA THERAPEUTICS AG (AT) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072711-A1 | ENANTIOMERICALLY PURE AMINES | PTMA, QPCTL, ATIC | TFPI2 1411/4885LMNA 2603/4885KDM4E 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.